palbociclib
pfizer,medsir
['breast', 'palbociclib', 'palbo', 'palmira']
 #asco23 palmira trial: randomized trial of continued palbociclib after progression in metastatic breast ca. 198 patients, 2:1 palbo v placebo. result: non-significant benefit to continued palbo, mainly in visceral disease, at 6 months; no benefit at 12 months.
Breast med oncology, chief hem/onc @NYPBrooklyn, prof clinical med @WeillCornell, ethics/spirituality in medicine; long time NY #Jets sufferer; tweets my own